Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS42001339EBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS42001337EBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS42001338EBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS42001340EBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS10007097HBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS10037314HBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS10039531HBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS10035112HBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS10020741HBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TVIS10048170HBVENSG00000154229.12protein_codingPRKCANoNo5578P17252
Q7Z727
TCGA Plot Options
Drug Information
GenePRKCA
DrugBank IDDB06641
Drug NamePerifosine
Target IDBE0001132
UniProt IDP17252
Regulation Type
PubMed IDs16528479
CitationsKnowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2006 Sep;24(5):435-9.
GroupsInvestigational
Direct ClassificationDialkyl phosphates
SMILESCCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1
Pathways
PharmGKB
ChEMBLCHEMBL372764